Head and Neck Cancer — Board Review Summary

PART I — HPV+ OROPHARYNX

TORS vs Primary RT/CRT

TrialDesignKey resultsBoard takeaway
ORATORPhase II RCT, N=68, T1-2 N0-2 (≤4 cm) OPSCC, HPV+/-; RT 70 Gy +/- chemo vs TORS + neck dissection +/- adjuvant therapyMDADI at 1y favored RT: 86.9 vs 80.1 (p=0.042), but difference did not meet the prespecified 10-point threshold; 5y MDADI converged; OS/PFS excellent in both armsNo survival-powered head-to-head winner; toxicity spectra differ more than efficacy
ORATOR2Phase II RCT, N=61, HPV+ only; de-escalated RT 60 Gy +/- weekly cisplatin vs de-escalated TOS + ND +/- reduced adjuvant RTStopped early for excess mortality in surgical arm; 2y OS 100% RT vs 90% TOS; 2y PFS 100% vs 86%De-escalated surgery was not safe in this trial; de-escalated primary RT performed extremely well
High-yield TORS principle: choose the modality that uses the fewest treatment modalities necessary. Avoid triple-modality treatment whenever possible. TORS fits best for well-lateralized, well-exposed T1-2 tonsil/base-of-tongue tumors with low ipsilateral nodal burden; bulky N2-3 disease, obvious ENE, poor exposure, or infiltrative midline disease favor primary CRT.

Definitive RT Alone vs CRT

Clinical settingPreferred approachSupporting detail
T1-2 N0RT alone reasonableStrong ASTRO support; excellent outcomes in carefully selected early-stage disease
T1-2 N1, single node ≤3 cmRT alone acceptable in selected HPV+ casesEspecially when chemo is contraindicated
T3-4 any NCRTLocally advanced disease standard
≥2 nodes or single node >3 cmCRTASTRO / NCCN standard
RTOG 1016 established that cetuximab is inferior to cisplatin in HPV+ OPC. With accelerated IMRT 70 Gy / 35 fx / 6 wk, 5y OS was 84.6% with cisplatin vs 77.9% with cetuximab; 5y PFS 78.4% vs 67.3%; locoregional failure 9.9% vs 17.3%. Severe toxicity rates were similar. Cisplatin + RT remains standard; cetuximab is only for true cisplatin-ineligible patients.

Definitive Dose / Fractionation / Volumes

ScenarioDose / fractionationNotes
Gross disease with concurrent systemic therapy70 Gy / 33-35 fxASTRO strong recommendation
Elective neck, sequential44-50 GyConventional elective range
Elective neck, SIB54-63 GyTypically 1.6-1.8 Gy/fx
RT alone, conventional68-70 GyT1-2 N0-1 single node ≤3 cm
RT alone, hypofractionated66-70 Gy at 2.1-2.2 Gy/fxFewer visits
RT alone, accelerated68-72 Gy over 6 weeksShorter overall time
Hyperfractionated RT74.4-81.6 Gy, 1.2 Gy BIDStrongly recommended for T3-4 when treating RT-alone style regimens

Elective Nodal Selection and Unilateral RT

Common elective levels: II-IV, retropharyngeal, and retrostyloid depending on nodal status.
Often omissible: level IB if no oral cavity involvement; level V if no naso/hypopharyngeal involvement.
Unilateral RT strong recommendation: HPV+ T1-2 palatine tonsil cancer confined to tonsillar fossa with either no positive node or a single node ≤3 cm and no ENE.
Bilateral RT required: base of tongue, soft palate, posterior pharyngeal wall, or tonsil tumors crossing midline / invading tongue base.

Definitive De-escalation: What Failed vs What May Still Work

NRG-HN005 was the sobering reminder that blanket dose reduction fails: 60 Gy + cisplatin and 60 Gy + nivolumab did not demonstrate non-inferiority versus standard 70 Gy + cisplatin. Clinical selection by HPV status and smoking history alone is not enough.
Investigational, not standard: biomarker-driven de-escalation is still alive. The MSK 30 ROC hypoxia-guided pilot used FMISO PET to select candidates for 30 Gy / 15 fx + platinum, with 2y locoregional control about 94.4% and no grade 3 RT-related mucositis/dysphagia. Other response-adapted strategies include mid-RT FDG-PET, mid-RT CT nodal response, and ctHPV DNA kinetics, but these remain trial-oriented.

Postoperative De-escalation in HPV+ OPC

StudyKey designMain resultTakeaway
ECOG 3311After TORS, low-risk observed; intermediate-risk randomized to 50 Gy vs 60 Gy; high-risk got 66 Gy + weekly cisplatin54-mo PFS: 94.9% for 50 Gy, 90.2% for 60 Gy; low-risk observation also excellent50 Gy is a viable intermediate-risk postoperative dose in selected HPV+ patients
MC1675 / DARTIntermediate-risk without ENE: de-escalated 30 Gy BID + weekly docetaxel vs 60 Gy; high-risk ENE cohort also randomizedIntermediate-risk cohort: excellent disease control with lower toxicity / better QOL; high-risk ENE cohort had worse PFS with de-escalationVery aggressive de-escalation may work in favorable intermediate-risk disease, but be cautious in ENE-positive / pN2 disease
Mucosal-sparing postoperative RT in select resected p16+ OPC treated only the nodal regions and omitted the primary mucosal site. At 2 years: 98% local control, 97% locoregional control, 100% OS, with only 3.3% PEG use overall and 0 PEG tubes in the proton cohort. Very promising, but still a selected strategy rather than universal standard.
Post-op HPV+ dose guide: high-risk ENE and/or positive margins 60-66 Gy; intermediate-risk 56-60 Gy; ECOG 3311-style de-escalation to 50 Gy is reasonable in carefully selected intermediate-risk HPV+ patients.

PART II — NASOPHARYNX CANCER

RT vs CRT vs IC-CRT

TrialDesignKey resultTakeaway
Intergroup 0099Stage III-IV NPC; RT alone vs RT 70 Gy + concurrent cisplatin then adjuvant PF3y PFS 69% vs 24%; 3y OS 78% vs 47%Historic landmark establishing CRT-based intensification
Chen 2012CCRT + adjuvant PF vs CCRT aloneNo significant benefit in FFS or OSAdjuvant PF after modern CCRT is controversial
NPC-0502Post-CRT EBV-positive patients; adjuvant GP vs observationNo significant benefitBiomarker-selected adjuvant PF/GP has not clearly rescued AC
Metronomic capecitabineHigh-risk LA-NPC after CCRT +/- IC; capecitabine 650 mg/m2 BID x 1 year vs observation3y FFS 85.3% vs 75.7%; OS 93.3% vs 86.1%; DMFS 89.2% vs 79.7%One of the strongest adjuvant-era positive studies
TPF ICTPF x3 then CCRT vs CCRT alone5y OS 85.6% vs 77.7%IC improves distant control and survival
GP ICGemcitabine/cisplatin x3 then CCRT vs CCRT aloneFinal 5y OS 87.9% vs 78.8%GP is a modern preferred IC regimen
MAC-NPCNetwork meta-analysis, 8,221 pts / 31 RCTsIC + CCRT ranked highest for OS, PFS, distant progression, and NPC-specific deathIC + CCRT is the preferred overall strategy in LA-NPC
Guo 2025TPF IC + CCRT vs CCRT + AC in N2-3, EBV-high-risk NPCNo PFS winner; IC better DMFS, AC better LR-FFSIC and AC solve different problems: distant vs local-regional control
NCCN 2026 practical framework: T1N0 and many low-risk T2N0 cases can still be treated with RT alone; CRT is the backbone for intermediate disease; and IC -> CRT is preferred for locoregionally advanced disease, especially bulky / EBV-high-risk presentations.

Elective Nodal Coverage: UNI vs WNI

Tang et al. phase III randomized 446 N0-N1 NPC patients to unilateral-neck irradiation (UNI) vs bilateral whole-neck irradiation (WNI). UNI was non-inferior: 5y regional RFS 95.0% vs 94.9%, OS 95.9% vs 93.1%. Only 2/446 patients had contralateral lower-neck recurrence, one in each arm.
Late toxicity in 5y disease-free survivorsWNIUNI
Hypothyroidism48%34%
Neck tissue damage / fibrosis46%29%
Dysphagia27%14%
Carotid stenosis26%15%
NPC nodal-coverage pearl: uninvolved contralateral lower neck is at extremely low risk in properly selected N0-N1 disease. Modern NPC practice is moving away from routine whole-neck treatment for everyone.

Post-Induction RT Dose / Volume De-escalation

StudyStrategyMain result
Yang / Xiang phase IIIPost-IC residual GTV got 70 Gy in both arms; resolved pre-IC GTV randomized to 70 Gy vs 64 GyNo difference in disease control or survival; 64 Gy arm had better xerostomia / cognitive outcomes
Tang 2025 phase IIIPost-IC soft-tissue GTV volume reduction vs conventional pre-IC GTV; both arms 70 Gy to GTV, 60-62 Gy high-risk CTV, 54-56 Gy low-risk CTV3y LRRFS 91.5% vs 91.2%, non-inferior; less acute mucositis and less late otitis/xerostomia with reduced-volume planning
NPC de-escalation rule to memorize: post-IC soft-tissue response can guide radical-dose volume reduction, but bony structures with initial invasion should still be delineated from pre-IC imaging and treated aggressively. IG-2024 moved toward endorsing post-IC GTV for the 70 Gy equivalent volume and lowered elective dose to about 50 Gy equivalent.

PART III — EARLY GLOTTIC LARYNX

T1N0 Partial Larynx / Single Vocal Cord RT

StudyPopulationLocal controlFunctional / toxicity signal
Erasmus MC / Tans 2022T1a mostly5y LC 97.1%Late grade 3+ 6.5%; voice improved over time
Al-Mamgani 2015T1a N02y LC 100% vs 92.2% WLRTAcute toxicity 17% vs 66% with WLRT; better voice outcomes
Elsharief 2026 RCTT1a N02y LC 100% SVCI vs 96% WLRTBetter VHI at 1y; no grade 3-4 toxicity
MD Anderson 2025T1-2/Tis N03y LRC 85.4% PLRT vs 90.8% WLRTLess acute dysphagia and better MDADI with PLRT
Main point: for T1a N0, partial-larynx or single-vocal-cord RT can achieve 97-100% local control with better voice / acute-toxicity profiles. For T2, data are less secure and local control may be lower, so caution is warranted.

NCCN Dose Standards for Early Glottic RT

StageDose options
T1 N063 Gy / 28 at 2.25 Gy/fx preferred; or 66 Gy / 33; or 50-52 Gy at 3.12-3.28 Gy/fx
T2 N064.8 Gy at 2.4 Gy/fx up to 70 Gy / 35

T2N0 Glottic: Add Chemo or Intensify RT?

T2N0 glottic disease has worse local control with RT alone than T1 disease, especially with impaired cord mobility, subglottic extension, anterior commissure involvement, or bulky GTV. Retrospective series suggest CRT can improve local control and voice preservation, but there is no dedicated randomized phase III CRT-vs-RT trial for T2N0 glottic cancer.
Practical board takeaway: "unfavorable T2" glottic cancer may justify treatment intensification either through CRT or altered-fractionation / accelerated RT. The deck's institutional examples favor considering chemo when there is possible paraglottic involvement, bulky primary, subglottic extension, or sluggish cords.

PART IV — LARYNX / HYPOPHARYNX, HPV-NEGATIVE: ELECTIVE NODAL DE-ESCALATION

Why This Is Different from Failed Gross-Disease De-escalation

The lecture makes a key conceptual distinction: gross-disease de-escalation failed in HPV+ OPC because macroscopic tumor has a steep dose-response curve. Elective nodal de-escalation targets microscopic disease, where the dose-response curve is shallower and de-escalation is therefore biologically more plausible.

Randomized and Prospective Data

StudyPopulation / designElective doseMain result
Nevens / DeschuymerBelgian phase III RCT, N=200, ~90% HPV-negative40 Gy vs 50 GyOnly 2 true elective failures per arm; lower salivary toxicity with 40 Gy
UPGRADE-RTDutch phase III RCT, N=300, RT alone for OP/larynx/hypopharynx43 Gy vs 50 Gy2y elective nodal recurrence 4.9% vs 4.3%; less acute grade 3+ dysphagia with 43 Gy
Sher phase IIDual-center, mixed HPV, most with concurrent chemo40 Gy / 20 + reduced elective volumes0 solitary elective nodal failures
Zakeri 202573 consecutive HPV-negative larynx / hypopharynx / p16-neg OPC / CUP pts40 Gy elective with CRT0 solitary elective nodal recurrences; all locoregional recurrences were in 70 Gy volumes
DEPENDHPV-negative stage IVa/b after neoadjuvant nivo + carbo/taxol; deep responders omitted elective volumes0 Gy elective in responders2y PFS 66%, OS 73%, with less mucositis, dermatitis, and dry mouth in de-escalated responders

Guideline Position

NCCN 2026 still lists elective dose as 44-50 Gy sequential or 54-63 Gy SIB. ASCO SCCUP 2020 already endorses a biologically equivalent elective dose range of roughly 40-50 Gy to negative nodal regions. So 40 Gy is evidence-based, but has been incorporated into guidelines unevenly.

PART V — ORAL CAVITY: PORT, CRT, AND PERIOPERATIVE IMMUNOTHERAPY

Surgery First, Then Pathology-Driven Adjuvant Therapy

Risk groupFeaturesUsual treatment implication
High riskENE and/or positive marginCategory 1 postoperative CRT
Intermediate riskClose margins, pT3-4, pN2-3, level IV/V nodes, PNI, vascular invasion, lymphatic invasionPORT, with selective discussion of systemic intensification

Landmark Postoperative Trials

TrialDesignMain resultBoard takeaway
EORTC 22931Post-op RT 66 Gy vs CRT with cisplatin 100 mg/m2 q3wk x35y OS 53% vs 40%; improved PFS and locoregional controlPost-op CRT clearly better in very high-risk patients
RTOG 9501Post-op RT 60 Gy +/- cisplatinLong-term benefit confined mainly to ENE / positive margin subgroup≥2 nodes alone did not clearly benefit from cisplatin
Bernier pooled 2005Pooled EORTC + RTOGENE and/or positive margins were the only features with consistent CRT benefit in both trialsThis created the modern ENE/+margin paradigm
Zumsteg 2025Updated combined analysis, n=744CRT improved OS overall (HR 0.81) and reduced cancer-specific mortality, but increased other-cause mortality; no interaction showing ENE/+margin uniquely predictiveProvocative challenge to the old paradigm, but does not erase the current guideline standard
Current exam answer: ENE and positive margins remain the strongest category 1 indications for postoperative CRT. The 2025 updated pooled analysis is important and provocative, but it should be interpreted as a challenge to dogma rather than a wholesale guideline replacement.

Postoperative Systemic Options

  • Preferred: cisplatin 100 mg/m2 on days 1, 22, and 43 of RT.
  • Common alternate schedule: weekly cisplatin 40 mg/m2.
  • Cisplatin-ineligible: docetaxel, or docetaxel + cetuximab in selected cases, but with weaker evidence.

Tian JCO 2024 — Early Oral Tongue pT1-2N0M0

In propensity-matched early oral tongue SCC, PORT improved outcomes in several adverse-feature subgroups. The strongest signal was for moderate-to-poor differentiation, where OS was 97% vs 69% and DFS 88% vs 50%. PNI/LVI, DOI >5 mm, and close margins also showed benefit. This is not yet a universal guideline rewrite, but it is a very testable modern nuance.

KEYNOTE-689

KEYNOTE-689 randomized 714 patients with resectable stage III-IVA HNSCC to perioperative pembrolizumab vs standard care. At 36 months, EFS favored pembrolizumab across CPS-defined groups: total population 57.6% vs 46.4% (HR 0.73), CPS ≥1 58.2% vs 44.9%, CPS ≥10 59.8% vs 45.9%. Surgery completion was about 88% in both arms. NCCN 2026 incorporates perioperative pembrolizumab for resectable PD-L1-positive locally advanced disease.
Post-op oral cavity dose pearl: high-risk volumes generally receive 60-66 Gy, with RT ideally beginning within 6 weeks of surgery.

CROSS-CUTTING HIGH-YIELD POINTS

  • ORS / TORS vs RT in HPV+ OPC: only ORATOR and ORATOR2 directly randomized surgery vs RT/CRT; there is still no survival-powered phase III head-to-head trial.
  • ORATOR: RT and TORS both yielded excellent oncologic outcomes; swallowing favored RT at 1 year, then converged.
  • ORATOR2: stopped early because of excess surgical-arm mortality; de-escalated RT performed extremely well.
  • RTOG 1016: cetuximab is inferior to cisplatin in HPV+ OPC and should not replace cisplatin in eligible patients.
  • HPV+ definitive standard: gross disease 70 Gy / 33-35 fx with cisplatin.
  • RT alone in HPV+ OPC: acceptable mainly for T1-2 N0-1 with a single node ≤3 cm or when chemo is contraindicated.
  • NRG-HN005: unselected dose reduction to 60 Gy failed; blanket definitive de-escalation is not standard.
  • Unilateral RT in HPV+ tonsil: reasonable when well lateralized and low nodal burden; BOT / soft palate / PPW / midline disease requires bilateral treatment.
  • ECOG 3311: postoperative 50 Gy is a key intermediate-risk HPV+ dose after TORS.
  • MC1675: aggressive postoperative de-escalation may work in intermediate-risk disease, but ENE-positive patients did worse with overly reduced therapy.
  • NPC systemic backbone: CCRT remains essential, but modern data favor IC + CCRT over CCRT + AC overall.
  • NPC adjuvant nuance: classic PF after CCRT is controversial, but metronomic capecitabine is a real positive adjuvant study.
  • NPC nodal coverage: unilateral-neck approaches can safely spare the contralateral lower neck in selected N0-1 patients and reduce late toxicity.
  • Post-IC NPC planning: residual soft-tissue GTV can guide the 70 Gy volume, but initially involved bone should still be respected from pre-IC imaging.
  • T1a glottic cancer: partial-larynx / single-vocal-cord RT is increasingly compelling, with excellent control and better voice / toxicity outcomes.
  • T2 glottic cancer: worse local control than T1; consider intensified RT or CRT for unfavorable features.
  • HPV-negative larynx/hypopharynx elective de-escalation: randomized data now support 40-43 Gy as a safe elective dose in selected settings.
  • Oral cavity surgery-first principle: ENE and positive margins remain the strongest indications for postoperative CRT.
  • Zumsteg 2025: important challenge to the ENE/+margin-only dogma, but not yet a wholesale guideline reversal.
  • KEYNOTE-689: first major perioperative immunotherapy advance incorporated into oral cavity / resectable LA HNSCC pathways.

CONSOLIDATED DOSE TABLE

SettingDose / regimenWhy it matters
HPV+ OPC definitive CRT70 Gy / 33-35 fxModern standard gross-disease dose
HPV+ OPC elective neck, sequential44-50 GyCommon conventional elective range
HPV+ OPC elective neck, SIB54-63 GySIB elective range
HPV+ OPC RT alone68-70 GyEarly-stage / chemo-ineligible approach
30 ROC pilot30 Gy / 15 fxInvestigational hypoxia-guided major de-escalation
ECOG 3311 intermediate risk50 GyKey postoperative HPV+ de-escalation dose
Post-op HPV+ high risk60-66 GyPositive margin / ENE postoperative range
NPC RT alone, early stage70 GyBackbone RT-alone dose
NPC post-IC resolved pre-IC GTV64 GyPhase III-supported reduced dose to resolved pre-IC disease
NPC high-risk CTV60-62 GyTang reduced-volume phase III schema
NPC low-risk CTV54-56 GyConventional low-risk dose in Tang phase III
Early glottic T1 N063 Gy / 28NCCN preferred conventional regimen
Early glottic T1 N0 alternative50-52 GyHypofractionated option
Glottic T2 N064.8-70 GyStandard definitive RT range
HPV-negative elective nodal de-escalation40-43 GySupported by Nevens / UPGRADE-RT
Oral cavity post-op RT60-66 GyHigh-risk postoperative range
Post-op concurrent cisplatin100 mg/m2Days 1, 22, 43 standard schedule

KEY LANDMARK TRIALS (memorize)

TrialDiseaseOne-line takeaway
ORATORHPV+/- OPSCCTORS and RT both work; functional tradeoffs differ more than control outcomes
ORATOR2HPV+ OPSCCDe-escalated surgery arm had excess mortality; de-escalated RT was strong
RTOG 1016HPV+ OPCCetuximab is inferior to cisplatin with RT
NRG-HN005HPV+ OPCBlanket definitive dose de-escalation to 60 Gy failed
ECOG 3311Post-op HPV+ OPC50 Gy is a key intermediate-risk postoperative dose after TORS
MC1675 / DARTPost-op HPV+ OPCAggressive de-escalation may work in favorable intermediate risk, but not safely in higher-risk ENE disease
Mucosal-sparing RTResected HPV+ OPCRegional-only postoperative RT is promising in selected patients
Intergroup 0099NPCEstablished CRT-based intensification as the landmark standard
Chen 2012NPCAdjuvant PF after CCRT did not clearly improve outcomes
Chen 2021 capecitabineNPCMetronomic adjuvant capecitabine improved FFS, OS, and DMFS
TPF (Sun 2016)NPCInduction TPF improved long-term survival over CCRT alone
GP (Zhang 2019)NPCInduction gemcitabine/cisplatin is a modern preferred IC regimen
MAC-NPCNPCIC + CCRT ranks highest overall among combined-modality strategies
Tang UNI vs WNINPC nodal coverageUpper-neck-only sparing is non-inferior in selected N0-1 patients and reduces late toxicity
Yang / XiangNPC post-IC planningResolved pre-IC disease can safely receive intermediate rather than full dose
Tang 2025 reduced-volume RTNPC post-IC planningPost-IC reduced-volume RT is non-inferior and less toxic
UPGRADE-RTHPV-negative HN elective neck43 Gy elective dose is safe and less toxic than 50 Gy
Nevens / DeschuymerHPV-negative HN elective neck40 Gy elective dose produced very few true elective failures
EORTC 22931Post-op oral cavity / HNSCCCRT improved OS, PFS, and locoregional control vs RT alone
RTOG 9501Post-op oral cavity / HNSCCLong-term CRT benefit was strongest in ENE / positive-margin disease
Bernier pooled 2005Post-op HNSCCCreated the ENE/+margin-only paradigm for category 1 postoperative CRT
Zumsteg 2025Post-op HNSCCChallenges the strict ENE/+margin-only paradigm, but with toxicity tradeoffs
KEYNOTE-689Resectable locally advanced HNSCCPerioperative pembrolizumab improved EFS and is now NCCN-incorporated
Tian 2024Early oral tongue SCCPORT may help selected pT1-2N0 patients with adverse features, especially moderate-poor differentiation